On Friday, Innoviva received an upgrade to its Relative Strength (RS) Rating, from 66 to 72.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the top-performing stocks typically have an RS Rating of over 80 as they begin their largest price moves. See if Innoviva can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
While it's not currently an ideal time to jump in, see if the stock is able to form a consolidation and break out.
Earnings growth picked up last quarter from -98% to -66%. But revenue gains fell from 33% to 7%.
The company earns the No. 140 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
